论文部分内容阅读
如何实现对严重危害人类健康疾病的精准治疗是目前医学界的难题和研究热点。随着“精准医疗”计划启动,药物设计也随之进入“精准”靶向药物分子设计时代。全球范围内患病人数最高的心血管疾病是目前全球范围内导致人类病死的主要疾病之一,远高于因肿瘤及其他疾病病死人数,而其中缺血性心肌疾病已成为威胁人类健康的头号杀手。目前,虽有多种治疗心肌缺血药物,但多数缺乏组织特异性,同时因缺血区血液循环障碍,使药物在缺血区的分布往往不甚理想。本研究综述并探讨了针对靶向于心肌缺血区的药物被动、主动以及理化实现机制与相关策略。
How to realize the precise treatment of diseases that seriously endanger human health is the current medical problems and research hot spots. With the launch of the “Precision Medicine” program, drug design has also entered the era of “targeted” molecular drug design. The world’s highest prevalence of cardiovascular disease is one of the leading causes of death in humans around the world, far higher than the number of deaths due to cancer and other diseases, of which ischemic cardiomyopathy has become the number one threat to human health Killer. At present, although there are many kinds of drugs for treating myocardial ischemia, most of them lack tissue specificity. At the same time, the distribution of drugs in the ischemic area is often not ideal due to the blood circulation disorder in the ischemic area. This study summarizes and discusses the mechanisms and related strategies of passive, active, physicochemical and chemical targeting of drugs targeted to myocardial ischemia.